Ratings Torrent Pharmaceuticals Limited NSE India S.E.

Equities

TORNTPHARM

INE685A01028

Market Closed - NSE India S.E. 07:43:49 2024-04-26 am EDT 5-day change 1st Jan Change
2,691 INR -0.12% Intraday chart for Torrent Pharmaceuticals Limited +5.97% +16.72%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • With an expected P/E ratio at 56.05 and 44.3 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+16.72% 10.92B -
+25.83% 661B
C+
+27.00% 566B
B
-6.76% 352B
C+
+20.34% 332B
B-
+3.00% 283B
C+
+13.09% 231B
B+
+5.46% 200B
B-
-9.61% 195B
A+
-6.26% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TORNTPHARM Stock
  4. TORNTPHARM Stock
  5. Ratings Torrent Pharmaceuticals Limited